Vol 14, No 4 (2018):183-187

The role of human T-lymphotropic virus (HTLV) in cardiovascular diseases: A review of literature

Samaneh Abolbashari, Majid Ghayour-Mobarhan, Mahmoud Ebrahimi, Zahra Meshkat

DOI: http://dx.doi.org/10.22122/arya.v1i1.1608


Cardiovascular diseases are a major cause of morbidity and mortality. Chronic inflammation is an important risk factor for atherosclerosis, and viral infections can cause cardiovascular disease by developing inflammation. Infection with human T-lymphotropic virus (HTLV) is endemic in some parts of the world such as Japan, Africa, Caribbean islands, South America, and Iran. HTLV-1 is an oncogenic retrovirus, and can cause adult T-cell leukemia/lymphoma (ATL or ATLL). It also causes HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). A number of inflammatory diseases such as uveitis, arthritis, and Sjogren's syndrome are also associated with the virus. A few case reports have shown the direct involvement of the heart in HTLV-1-positive patients who develop ATLL. The purpose of this study was to review the literature relevant with the role of HTLV in cardiovascular diseases.


Cardiovascular Disease; HTLV Infection; Atherosclerosis

Full Text:



Rosenfeld ME. Inflammation and atherosclerosis: Direct versus indirect mechanisms. Curr Opin Pharmacol 2013; 13(2): 154-60.

Campbell LA, Rosenfeld ME. Infection and atherosclerosis development. Arch Med Res 2015; 46(5): 339-50.

Ibrahim AI, Obeid MT, Jouma MJ, Moasis GA, Al-Richane WL, Kindermann I, et al. Detection of herpes simplex virus, cytomegalovirus and Epstein-Barr virus DNA in atherosclerotic plaques and in unaffected bypass grafts. J Clin Virol 2005; 32(1): 29-32.

Bangham CR, Cook LB, Melamed A. HTLV-1 clonality in adult T-cell leukaemia and non-malignant HTLV-1 infection. Semin Cancer Biol 2014; 26: 89-98.

Ahmadi GS, Shirdel A, Assarehzadegan MA, Hassannia T, Rahimi H, Miri R, et al. Human T lymphotropic virus type I (HTLV-I) oncogenesis: Molecular aspects of virus and host interactions in pathogenesis of adult t cell leukemia/lymphoma (ATL). Iran J Basic Med Sci 2013; 16(3): 179-95.

Shoeibi A, Etemadi M, Moghaddam AA, Amini M, Boostani R. "HTLV-i infection" twenty-year research in neurology department of Mashhad University of Medical Sciences. Iran J Basic Med Sci 2013; 16(3): 202-7.

Quaresma JA, Yoshikawa GT, Koyama RV, Dias GA, Fujihara S, Fuzii HT. HTLV-1, Immune Response and Autoimmunity. Viruses 2015; 8(1).

Boxus M, Willems L. Mechanisms of HTLV-1 persistence and transformation. Br J Cancer 2009; 101(9): 1497-501.

Baydoun HH, Bellon M, Nicot C. HTLV-1 Yin and Yang: Rex and p30 master regulators of viral mRNA trafficking. AIDS Rev 2008; 10(4): 195-204.

Vrielink H, Reesink HW. HTLV-I/II prevalence in different geographic locations. Transfus Med Rev 2004; 18(1): 46-57.

Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene 2005; 24(39): 6058-68.

Safai B, Huang JL, Boeri E, Farid R, Raafat J, Schutzer P, et al. Prevalence of HTLV type I infection in Iran: A serological and genetic study. AIDS Res Hum Retroviruses 1996; 12(12): 1185-90.

Hedayati-Moghaddam MR, Fathimoghadam F, Eftekharzadeh Mashhadi I, Soghandi L, Bidkhori HR. Epidemiology of HTLV-1 in Neyshabour, Northeast of Iran. Iran Red Crescent Med J 2011; 13(6): 424-7.

Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 Infection. Front Microbiol 2012; 3: 388.

Verdonck K, Gonzalez E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: Recent knowledge about an ancient infection. Lancet Infect Dis 2007; 7(4): 266-81.

Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F, Bidkhori HR, Shamsian SK, Ahmadi S, et al. High prevalence of HTLV-I infection in Mashhad, Northeast Iran: A population-based seroepidemiology survey. J Clin Virol 2011; 52(3): 172-6.

Azarpazhooh MR, Hasanpour K, Ghanbari M, Rezaee SA, Mashkani B, Hedayati-Moghaddam MR, et al. Human T-lymphotropic virus type 1 prevalence in northeastern Iran, Sabzevar: An epidemiologic-based study and phylogenetic analysis. AIDS Res Hum Retroviruses 2012; 28(9): 1095-101.

Araya N, Sato T, Coler-Reilly A, Yagishita N, Yamano Y. Developing novel treatments for HTLV-1-associated myelopathy (HAM) by investigating molecular pathomechanisms. Nihon Rinsho Meneki Gakkai Kaishi 2016; 39(3): 207-12.

Buggage RR. Ocular manifestations of human T-cell lymphotropic virus type 1 infection. Curr Opin Ophthalmol 2003; 14(6): 420-5.

Eguchi K, Matsuoka N, Ida H, Nakashima M, Sakai M, Sakito S, et al. Primary Sjogren's syndrome with antibodies to HTLV-I: Clinical and laboratory features. Ann Rheum Dis 1992; 51(6): 769-76.

Nishioka K, Maruyama I, Sato K, Kitajima I, Nakajima Y, Osame M. Chronic inflammatory arthropathy associated with HTLV-I. Lancet 1989; 1(8635): 441.

Gilbert DT, Morgan O, Smikle MF, Simeon D, Barton EN. HTLV-1 associated polymyositis in Jamaica. Acta Neurol Scand 2001; 104(2): 101-4.

Olsen RG, Tarr MJ, Mathes LE, Whisler R, Du Plessis D, Schulz EJ, et al. Serological and virological evidence of human T-lymphotropic virus in systemic lupus erythematosus. Med Microbiol Immunol 1987; 176(2): 53-64.

Araya N, Sato T, Yagishita N, Ando H, Utsunomiya A, Jacobson S, et al. Human T-lymphotropic virus type 1 (HTLV-1) and regulatory T cells in HTLV-1-associated neuroinflammatory disease. Viruses 2011; 3(9): 1532-48.

Hisada M, Chatterjee N, Zhang M, Battjes RJ, Goedert JJ. Increased hepatitis C virus load among injection drug users infected with human immunodeficiency virus and human T lymphotropic virus type II. J Infect Dis 2003; 188(6): 891-7.

Castro E, Roger E. Hepatitis C virus/human T lymphotropic virus 1/2 co-infection: Regional burden and virological outcomes in people who inject drugs. World J Virol 2016; 5(2): 68-72.

Rezaee-Zavareh MS, Tohidi M, Sabouri A, Ramezani-Binabaj M, Sadeghi-Ghahrodi M, Einollahi B. Infectious and coronary artery disease. ARYA Atheroscler 2016; 12(1): 41-9.

Ouaguia L, Mrizak D, Renaud S, Morales O, Delhem N. Control of the inflammatory response mechanisms mediated by natural and induced regulatory T-cells in HCV-, HTLV-1-, and EBV-associated cancers. Mediators Inflamm 2014; 2014: 564296.

Layegh P, Shoeibi A, Nikkhah K, Ghabeli Juibary A, Raftari S, Darbarpanah S, et al. Can HTLV-1 infection be a potential risk factor for atherosclerosis? Intervirology 2014; 57(6): 365-8.

Farid HR, Jabbari F, Shabestari M, Rezaee SA, Gharivani Y, Valizadeh N, et al. Human T Lymphotropic Virus Type I (HTLV-I) is a Risk Factor for Coronary Artery Disease. Iran J Basic Med Sci 2013; 16(3): 217-20.

Moran AE, Roth GA, Narula J, Mensah GA. 1990-2010 global cardiovascular disease atlas. Glob Heart 2014; 9(1): 3-16.

Ohishi K, Nagasato K, Aoi W, Nakamura T, Ichinose K, Nishiura Y, et al. Circadian rhythms of blood pressure and heart rate in patients with human T-lymphotropic virus type-I-associated myelopathy. Tohoku J Exp Med 1993; 169(1): 67-75.

Gabarre J, Gessain A, Raphael M, Merle-Beral H, Dubourg O, Fourcade C, et al. Adult T-cell leukemia/lymphoma revealed by a surgically cured cardiac valve lymphomatous involvement in an Iranian woman: Cclinical, immunopathological and viromolecular studies. Leukemia 1993; 7(11): 1904-9.

Daisley H, Charles WP. Fatal metastatic calcification in a patient with HTLV-1-associated lymphoma. West Indian Med J 1993; 42(1): 37-9.

Daisley H, Charles W. Cardiac involvement with lymphoma/leukemia: A report of three autopsy cases. Leukemia 1997; 11(Suppl 3): 522-4.

Furukawa Y, Tanaka K, Hasuike T, Hirai M, Misu K, Ohira H, et al. Adult T-cell leukemia lymphoma with metastatic calcification. Rinsho Byori 1991; 39(8): 886-90.

Toyama T, Kubuki Y, Okamoto M, Hidaka T, Ishizaki J, Tsubouchi H. ATL (lymphoma type) presented with a mass formation in the heart. Rinsho Ketsueki 2002; 43(12): 1055-60.

Shepherd SJ, Wong D, Mahadeva U, Goldsmith D, Shankar-Hari M, Ostermann M. Fatal cardiovascular instability secondary to hypercalcaemia and intracellular calcium deposition complicating T-cell leukaemia-lymphoma. JRSM Open 2016; 7(5): 2054270415608119.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 4.0

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.